Mereo BioPharma Group Past Earnings Performance
Past criteria checks 0/6
Mereo BioPharma Group has been growing earnings at an average annual rate of 20.3%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 22.8% per year.
Key information
20.3%
Earnings growth rate
49.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 22.8% |
| Return on equity | -58.3% |
| Net Margin | -294.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Revenue & Expenses BreakdownBeta
How Mereo BioPharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -29 | 18 | 16 |
| 30 Sep 23 | 9 | -32 | 23 | 19 |
| 30 Jun 23 | 9 | -33 | 26 | 25 |
| 31 Mar 23 | 4 | -37 | 25 | 27 |
| 31 Dec 22 | 0 | -42 | 26 | 28 |
| 30 Sep 22 | 0 | -31 | 22 | 29 |
| 30 Jun 22 | 0 | -23 | 20 | 33 |
| 31 Mar 22 | 24 | -4 | 21 | 33 |
| 31 Dec 21 | 49 | 17 | 22 | 32 |
| 30 Sep 21 | 49 | -10 | 25 | 28 |
| 30 Jun 21 | 50 | -37 | 30 | 25 |
| 31 Mar 21 | 25 | -131 | 30 | 23 |
| 31 Dec 20 | 0 | -224 | 29 | 22 |
| 30 Sep 20 | 0 | -198 | 25 | 24 |
| 30 Jun 20 | 0 | -177 | 21 | 25 |
| 31 Mar 20 | 0 | -111 | 20 | 27 |
| 31 Dec 19 | 0 | -46 | 21 | 31 |
| 30 Sep 19 | 0 | -41 | 18 | 29 |
| 30 Jun 19 | 0 | -40 | 18 | 30 |
| 31 Mar 19 | 0 | -41 | 17 | 30 |
| 31 Dec 18 | 0 | -41 | 15 | 29 |
| 30 Sep 18 | 0 | -42 | 15 | 30 |
| 30 Jun 18 | 0 | -44 | 14 | 32 |
| 31 Mar 18 | 0 | -50 | 15 | 41 |
| 31 Dec 17 | 0 | -52 | 14 | 47 |
| 30 Sep 17 | 0 | -50 | 14 | 47 |
| 30 Jun 17 | 0 | -47 | 12 | 45 |
| 31 Mar 17 | 0 | -41 | 13 | 37 |
| 31 Dec 16 | 0 | -35 | 14 | 30 |
| 30 Jun 16 | 0 | -39 | 22 | 23 |
Quality Earnings: MREO is currently unprofitable.
Growing Profit Margin: MREO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MREO is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare MREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MREO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MREO has a negative Return on Equity (-58.31%), as it is currently unprofitable.